Aitziber Buqué

10.4k citations

51 papers · 6.2k indexed · 3 hit papers · h-index 25

Impact in

Immunology top 0.5%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Immune cells in cancer
- Phagocytosis and Immune Regulation
- interferon and immune responses
Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research

Papers in ⓘ

Immunology 34
- Immunotherapy and Immune Responses 19
- Immune Cell Function and Interaction 14
- interferon and immune responses 7
- Phagocytosis and Immune Regulation 5
Oncology 29
- Cancer Immunotherapy and Biomarkers 13
- Cancer-related Molecular Pathways 7
- CAR-T cell therapy research 6
- Cancer Cells and Metastasis 4

Co-authors: Lorenzo Galluzzi (40 shared papers)Guido Kroemer (24 shared papers)Laurence Zitvogel (19 shared papers)Oliver Kepp (8 shared papers)Juliette Humeau (4 shared papers)Norma Bloy (26 shared papers)Giulia Petroni (12 shared papers)Takahiro Yamazaki (13 shared papers)
Journals: OncoImmunology (17 papers)Trends in cancer (4 papers)Nature reviews. Immunology (3 papers)PLoS ONE (2 papers)Cancer Cell (2 papers)
Partner nations: United States France Spain

In The Last Decade

Aitziber Buqué

49 papers receiving 6.2k citations

Hit Papers

align trajectories log scale

Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors 2020 · 932 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2020 Nature Reviews Clinical Oncology
2016 Nature reviews. Immunology
2015 Cancer Cell

Peers

Countries citing papers authored by Aitziber Buqué

Since Specialization

Citations

This map shows the geographic impact of Aitziber Buqué's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aitziber Buqué with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aitziber Buqué more than expected).

Fields of papers citing papers by Aitziber Buqué

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aitziber Buqué. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aitziber Buqué. The network helps show where Aitziber Buqué may publish in the future.

Co-authors

The 25 scholars most cited alongside Aitziber Buqué, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Aitziber Buqué Line = papers co-authored together Aitziber Buqué links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 51 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Immunogenic cell death in cancer and infectious disease Nature reviews. Immunology ·Lorenzo Galluzzi, Aitziber Buqué, Oliver Kepp, Laurence Zitvogel, Guido Kroemer Hit paper breakdown →	2016	2246
2	Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents Cancer Cell ·Lorenzo Galluzzi, Aitziber Buqué, Oliver Kepp, Laurence Zitvogel, Guido Kroemer Hit paper breakdown →	2015	1141
3	Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors Nature Reviews Clinical Oncology ·Lorenzo Galluzzi, Juliette Humeau, Aitziber Buqué, Laurence Zitvogel, Guido Kroemer Hit paper breakdown →	2020	932
4	Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy Nature Immunology ·Takahiro Yamazaki, Alexander Kirchmair, Ai Sato, Aitziber Buqué, Marissa Rybstein, Giulia Petroni, Norma Bloy, Francesca Finotello, Lena Stafford, Esther Navarro Manzano, Francisco Ayala, Elena García-Martínez, Silvia C. Formenti, Zlatko Trajanoski, Lorenzo Galluzzi	2020	234
5	Immunomodulation by targeted anticancer agents Cancer Cell ·Giulia Petroni, Aitziber Buqué, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi	2020	147
6	Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy OncoImmunology ·Kristina Iribarren, Norma Bloy, Aitziber Buqué, Isabelle Cremer, Alexander Eggermont, Wolf H. Fridman, Jitka Fučíková, Jérôme Galon, Radek Špíšek, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi	2015	108
7	Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications OncoImmunology ·Aitziber Buqué, Norma Bloy, Fernando Aranda, Francesca Castoldi, Alexander Eggermont, Isabelle Cremer, Wolf H. Fridman, Jitka Fučíková, Jérôme Galon, Aurélien Marabelle, Radek Špíšek, Éric Tartour, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi	2015	103
8	Apoptotic caspases inhibit abscopal responses to radiation and identify a new prognostic biomarker for breast cancer patients OncoImmunology ·María E. Rodríguez-Ruiz, Aitziber Buqué, Michal Hensler, Jonathan Chen, Norma Bloy, Giulia Petroni, Ai Sato, Takahiro Yamazaki, Jitka Fučíková, Lorenzo Galluzzi	2019	99
9	Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment Nature Reviews Drug Discovery ·Giulia Petroni, Aitziber Buqué, Lisa M. Coussens, Lorenzo Galluzzi	2022	97
10	eIF2α phosphorylation as a biomarker of immunogenic cell death Seminars in Cancer Biology ·Oliver Kepp, Michaëla Semeraro, José Manuel Bravo‐San Pedro, Norma Bloy, Aitziber Buqué, Xing Huang, Heng Zhou, Laura Senovilla, Guido Kroemer, Lorenzo Galluzzi	2015	95
11	Trial Watch—Oncolytic viruses and cancer therapy OncoImmunology ·Jonathan Pol, Aitziber Buqué, Fernando Aranda, Norma Bloy, Isabelle Cremer, Alexander Eggermont, Philippe Erbs, Jitka Fučíková, Jérôme Galon, Jean‐Marc Limacher, Xavier Préville, Catherine Sautès‐Fridman, Radek Špíšek, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi	2015	92
12	Trial Watch: Peptide-based anticancer vaccines OncoImmunology ·Jonathan Pol, Norma Bloy, Aitziber Buqué, Alexander Eggermont, Isabelle Cremer, Catherine Sautès‐Fridman, Jérôme Galon, Éric Tartour, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi	2015	91
13	PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models OncoImmunology ·Takahiro Yamazaki, Aitziber Buqué, Tyler D. Ames, Lorenzo Galluzzi	2020	88
14	Trial Watch: Immunotherapy plus radiation therapy for oncological indications OncoImmunology ·Erika Vacchelli, Norma Bloy, Fernando Aranda, Aitziber Buqué, Isabelle Cremer, Sandra Demaria, Alexander Eggermont, Silvia C. Formenti, Wolf H. Fridman, Jitka Fučíková, Jérôme Galon, Radek Špíšek, Éric Tartour, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi	2016	67
15	Modeling Tumor Immunology and Immunotherapy in Mice Trends in cancer ·Aitziber Buqué, Lorenzo Galluzzi	2018	56
16	The ratio of CD8⁺/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma in situ OncoImmunology ·Michaëla Semeraro, Julien Adam, Gautier Stoll, Émilie Louvet, Kariman Chaba, Vichnou Poirier-Colame, Allan Sauvat, Laura Senovilla, Erika Vacchelli, Norma Bloy, Juliette Humeau, Aitziber Buqué, Oliver Kepp, Laurence Zitvogel, Fabrice André, Marie‐Christine Mathieu, Suzette Delaloge, Guido Kroemer	2016	47
17	Trial Watch—Immunostimulation with cytokines in cancer therapy OncoImmunology ·Erika Vacchelli, Fernando Aranda, Norma Bloy, Aitziber Buqué, Isabelle Cremer, Alexander Eggermont, Wolf H. Fridman, Jitka Fučíková, Jérôme Galon, Radek Špíšek, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi	2015	44
18	Trial Watch—Small molecules targeting the immunological tumor microenvironment for cancer therapy OncoImmunology ·Aitziber Buqué, Norma Bloy, Fernando Aranda, Isabelle Cremer, Alexander Eggermont, Wolf H. Fridman, Jitka Fučíková, Jérôme Galon, Radek Špíšek, Éric Tartour, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi	2016	43
19	Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy OncoImmunology ·Elena García-Martínez, Melody Smith, Aitziber Buqué, Fernando Aranda, Francisco Ayala, Alejandra Ivars, Manuel Sánchez Cánovas, M.A. Vicente Conesa, Jitka Fučíková, Radek Špíšek, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi	2018	39
20	Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER+ Breast Cancer Clinical Cancer Research ·Giulia Petroni, Aitziber Buqué, Takahiro Yamazaki, Norma Bloy, Maurizio Di Liberto, Selina Chen‐Kiang, Silvia C. Formenti, Lorenzo Galluzzi	2021	36

About Aitziber Buqué

Aitziber Buqué is a scholar working on Immunology, Oncology, Biotechnology, Toxicology and Molecular Biology, having authored 51 papers that have together received 6.2k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (19 papers), Immune Cell Function and Interaction (14 papers), Cancer Immunotherapy and Biomarkers (13 papers), Cancer-related Molecular Pathways (7 papers), interferon and immune responses (7 papers), CAR-T cell therapy research (6 papers), Phagocytosis and Immune Regulation (5 papers) and Cancer Cells and Metastasis (4 papers). The work is most often cited by research in Immunology (3.2k citations), Oncology (3.3k citations), Physiology (168 citations), Cancer Research (495 citations) and Biotechnology (277 citations). Aitziber Buqué has collaborated with scholars based in United States, France and Spain. Frequent co-authors include Lorenzo Galluzzi, Guido Kroemer, Laurence Zitvogel, Oliver Kepp, Juliette Humeau, Norma Bloy, Giulia Petroni, Takahiro Yamazaki, Jitka Fučíková and Isabelle Cremer. Their work appears in journals such as OncoImmunology, Trends in cancer, Nature reviews. Immunology, PLoS ONE and Cancer Cell.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact